NCT02939547View on ClinicalTrials.gov

Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 11, 2017

Primary Completion Date

February 10, 2020

Study Completion Date

February 10, 2020

Conditions
Niemann-Pick Disease, Type C1
Interventions
DRUG

Hydroxypropyl-beta-cyclodextrin

Used in the treatment of Niemann-Pick Disease C1 ( NPC1)

Trial Locations (2)

94609

UCSF Benioff Children's Hospital Oakland, Oakland

07960

Atlantic Health System/Morristown Medical Center, Morristown

Sponsors
All Listed Sponsors
lead

Cyclo Therapeutics, Inc.

INDUSTRY

NCT02939547 - Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1) | Biotech Hunter | Biotech Hunter